Preliminary results with PDC lung01 in monotherapy and at low dose with pembrolizumab evoke acceptable safety profile, immunological activity and promising tumour response in Non-Small Cell Lung Cancer
Part A results from the two-part Phase 2 LILAC study show litifilimab significantly reduced disease activity based on active joint count in people with.
Positive results for Biogen s lupus drug published in NEJM pmlive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pmlive.com Daily Mail and Mail on Sunday newspapers.
Biogen Inc : Biogen Announces First Patient Dosed in Phase 3 Systemic Lupus Erythematosus Study finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.